Longitudinal Study of Different Surgical Approaches in Chinese Patients of Uterine Cervical Cancer

Sponsor
Lei Li (Other)
Overall Status
Recruiting
CT.gov ID
NCT03738969
Collaborator
(none)
3,000
1
61.4
48.9

Study Details

Study Description

Brief Summary

This multi-center longitudinal study aims to compare the survival outcomes (including overall survival, progression-free survival and disease-free survival between uterine cervical patients receiving different surgical routes (vaginal, laparotomy and laparoscopy), which is the primary study objective. All clinical and pathological data would be retracted from case reviews, and all survival data would be reached by clinic, telephone and mail follow-up. This study also would analyze the impact on survival outcomes of other factors, including nerve-sparing techniques, neoadjuvant chemotherapy, neoadjuvant radiotherapy and infection of human papillomavirus. The predictive effects of different following protocol and imaging plans will be also compared. Last, the influences of surgical routes on the fertility outcomes (pregnancy and its complications) and the ovarian reserve are important secondary study objectives.

Condition or Disease Intervention/Treatment Phase
  • Procedure: Laparotomic radical hysterectomy
  • Procedure: Laparoscopic radical hysterectomy

Study Design

Study Type:
Observational
Anticipated Enrollment :
3000 participants
Observational Model:
Cohort
Time Perspective:
Retrospective
Official Title:
Longitudinal Study of Different Surgical Approaches in Chinese Patients of Cervical Cancer
Actual Study Start Date :
Nov 10, 2018
Anticipated Primary Completion Date :
Dec 23, 2022
Anticipated Study Completion Date :
Dec 23, 2023

Arms and Interventions

Arm Intervention/Treatment
Laparotomy group

Patients in this group accepted laparotomic radical hysterectomy for cervical cancer.

Procedure: Laparotomic radical hysterectomy
Radical hysterectomy applied by laparotomy

Laparoscopy group

Patients in this group accepted laparoscopic or robotic radical hysterectomy for cervical cancer.

Procedure: Laparoscopic radical hysterectomy
Radical hysterectomy applied by laparoscopic

Outcome Measures

Primary Outcome Measures

  1. Progression-free survival [Five years]

    Length of time during and after the treatment of cervical cancer, that a patient lives with the disease but it does not get worse

Secondary Outcome Measures

  1. Overall survival [Five years]

    The length of time from either the date of diagnosis or the start of treatment for a disease, such as cancer, that patients diagnosed with the disease are still alive. In a clinical trial, measuring the overall survival is one way to see how well a new treatment works.

  2. Disease-free survival [Five years]

    In cancer, the length of time after primary treatment for a cancer ends that the patient survives without any signs or symptoms of that cancer. In a clinical trial, measuring the disease-free survival is one way to see how well a new treatment works.

Other Outcome Measures

  1. Pregnancy rate [Five years]

    Proportion of patients who have been pregnant after the fertility-preserving radical trachelectomy

Eligibility Criteria

Criteria

Ages Eligible for Study:
N/A and Older
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Pathological confirmed as uterine cervical cancer

  • Having definite clinical information

  • Having received radical hysterectomy or trachelectomy

Exclusion Criteria:
  • Not satisfying any of the inclusion criteria

Contacts and Locations

Locations

Site City State Country Postal Code
1 Lei Li Beijing Beijing China 100730

Sponsors and Collaborators

  • Lei Li

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Lei Li, Professor, Peking Union Medical College Hospital
ClinicalTrials.gov Identifier:
NCT03738969
Other Study ID Numbers:
  • SACCC
First Posted:
Nov 13, 2018
Last Update Posted:
Nov 14, 2018
Last Verified:
Nov 1, 2018
Individual Participant Data (IPD) Sharing Statement:
Yes
Plan to Share IPD:
Yes
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Nov 14, 2018